Registration Dossier

Environmental fate & pathways

Endpoint summary

Administrative data

Description of key information

Additional information

Exxon Biomedical Sciences (2004) is a GLP compliant, ready biodegradability study on DCPD/Codimer Concentrate, which has been read across to DCPD. The study, which follows OECD guideline 301F, showed 0% biodegradation in 28 days and therefore DCPD is considered to be not readily biodegradable.

This is supported by the results of a MITI study, used in the OECD SIDS but not available for review. The SIDS Initial assessment (1997) identified a MITI report which indicated that under aerobic conditions dicylopentadiene (DCPD) showed 0% degradation after 2 weeks and classed the substance as not readily biodegradable.

For DCPD the Biowin 3 prediction of ultimate degradation time is 2.90 and the probabilities of fast degradation under Biowin 2 and 6 are 0.76 and 0.23 respectively, with an overall prediction of not readily biodegradable. BioHCwin V1.01 predicts the half life of dicylopentadiene to be 21.4 days.

The results from both QSAR indicate that DCPD is expected not to be readily biodegradable. On the basis of the available data and the QSAR prediction, DCPD is considered to be P but not vP.